不同他汀对绝经后高血压血脂异常合并糖耐量减低患者的疗效观察  

Effects of Rosuvastatin and Pitavastatin on Postmenopausal Patients with Hypertension and Lipid Abnormalities Complicated with Impaired Glucose Tolerance

作　　者：范瑞云 石磊 董均杰 杨静茹[2] 

机构地区：[1]解放军第二七二医院急诊急救中心,天津300020 [2]解放军第二六六医院

出　　处：《解放军预防医学杂志》2017年第6期571-574,共4页Journal of Preventive Medicine of Chinese People's Liberation Army

基　　金：天津市重点攻关项目(No.15KG127)

摘　　要：目的观察瑞舒伐他汀和匹伐他汀治疗绝经后女性高血压血脂异常合并糖耐量减低(IGT)的效果。方法连续选取2013年5月至2014年6月间就诊的绝经后高血压血脂异常伴IGT患者242例,随机分为瑞舒伐他汀组(10 mg/d,n=121)和匹伐他汀组(2 mg/d,n=121),观察两组治疗前和治疗后2、6、12、24个月总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、甘油三酯(TG)、空腹血糖、餐后2 h血糖及新发糖尿病例数。结果治疗前后比较:两组治疗后与本组治疗前比较,TC、LDL-C(2、6、12、24个月时)明显降低(P<0.01)、HDL-C(12、24个月时)明显升高(P<0.05)。组间比较:瑞舒伐他汀组与匹伐他汀组同期比较,TC和LDL-C均降低明显(P<0.05),匹伐他汀组HDL-C(24个月时)升高较瑞舒伐他汀组明显(P<0.05)。瑞舒伐他汀组治疗12、24个月时与本组治疗前比较,空腹血糖、糖化血红蛋白均升高(P<0.05);匹伐他汀组与本组治疗前比较,空腹血糖、糖化血红蛋白无明显变化。治疗12、24个月时新发糖尿病例数分别为瑞舒伐他汀组10、21例,匹伐他汀组8、14例(P<0.05)。结论常规剂量的瑞舒伐他汀降低绝经后高血压高血脂合并IGT患者的血脂水平的效果优于常规剂量的匹伐他汀,匹伐他汀对糖耐量减低患者血糖影响小于瑞舒伐他汀。ABSTRACT ： Objective To investigate the effects of rosuvastatin and pitavastatin on postmenopausal patients with hyperten- sion and lipid abnormalities complicated with impaired glucose tolerance （IGT）. Methods A total of 242 consecutive postmenopa- usal patients with hypertension and lipid abnormalities complicated with impaired glucose tolerance （IGT） treated in our hospital between July 2013 and August 2014 were studied. The patients were randomly and equally divided into two groups ： the rosuvasta- tin group that received rosuvastatinl0mg/day and the pitavastatin group that was given pitavastatin 2 rag/day. The levels of total cholesterol （TC）, low-density lipoprotein cholesterol （LDL-C）, high density lipoprotein cholesterol （HDL-C）, trigalloyl glyc- erol （TG）before medication and at 2,6, 12, 24 months after medication, fasting blood glucose （FBG）, 2-hour postprandial glu- cose （2 hPBG） and the number of new cases of diabetes were compared between the two groups. Results Compared to baseline, the levels of total cholesterol and LDL-C were significantly reduced after treatment （2,6,12,24 months ） in both groups（P〈0.01 ） while the level of HDL-C （12,24 months P〈0.05 ） was significantly increased. Levels of TC and LDL-C were decreased more sig- nificantly in the rosuvastatin group than in the pitavastatin group （2,6,12,24 months P〈0.05 ）, but the level of HDL-C was in- creased more significantly in the pitavastat group than in the rosuvastat group （24 months P〈0.05 ）. After 12 and 24 months of treatment, levels of FBG and 2hPBG were increased in the rosuvastatin group（ P〈0.05 ） ,and there was no statistically significant difference in FBG and 2hPBG levels in the pitavastatin group（ P〉0.05 ） o The number of new-onset patients of diabetes was 10 （12 months）and 21 （24 months）in the rosuvastatin group, but was 8 （12 months） .and 14 （24 months）in the pitavastatin group （P〈0. 05 ）. Conclusion Compared with pitavastatin, t

关 键 词：瑞舒伐他汀 匹伐他汀 绝经后 高血压 血脂异常 糖耐量减低 

分 类 号：R711.51[医药卫生—妇产科学] R587.1[医药卫生—临床医学]